RD-Biotech’s new building was officially inaugurated this Friday evening in the heart of the Temis Santé technology park. Located on rue Françoise-Dolto, it is three times larger than the old premises, which had become too cramped due to the strong growth of the Bisonne company. The company was – and still is – very active by participating in the development of Pfizer’s Covid-19 vaccine. 0
This is an important moment for the Bisontinental flagship RD-Biotech, a laboratory that carries out R&D for clients in the biotechnology and pharmaceutical industries. The company, which was – and still is – very active during the health crisis by participating in the development of Pfizer’s Covid-19 vaccine, inaugurated its new building in the Hauts-du-Chazal sector on Friday, November 26th. “This is a response to the company’s growth in recent years,” says director Philippe Dulieu proudly, but modestly. Born2Invest mobile app makes it easy for you to keep informed, to intuitively move from story to story, and from section to section. Our clean design lets you read articles without clutter, and use the app with no limits on how many articles you can view. Read more about RD-Biotech and get comprehensive access to global crowdfunding business, stock market, finance news , and trending topics with our companion app. 3.5 million investment
The new establishment on rue Françoise-Dolto has certainly been invested since last April. But the health crisis delayed this symbolic moment in front of relatives and elected officials. The premises located on rue Henri-Baigue had indeed become too cramped for the manager, who created the company in 2002 with two partners. As the company grew, “we pushed the walls”, but “at a certain point, we decided to embark on this ambitious project. The result: in these new modern premises in the heart of the Temis Health Park, the surface area has been tripled to accommodate the 45 employees in 1,250 m². “We started this project in 2018,” continued the executive. The investment is $4 million (€3.5 million). […] Today, it’s a good step that we are taking, it allows us to take stock of where we are, and where we are going!” continued Philippe Dulieu. All eyes are now on this other project: the construction of a 1,200 m² building not far from there. A “factory” intended for the production of DNA (GMP grade) to meet growing demand, and which should be the only production site of this type in France. This site has been selected as part of the France Recovery Plan. RD-Biotech hopes to hire about 15 people here within the next two years, “and even about 50 employees within 3-4 years.”
__
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our  disclaimer  for more information. This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these  important disclosures . First published in  L’EST , a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail. Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

RD-Biotech Inaugurates its New Building in the Heart of Temis Santé

1 July 2020
We’re pleased to welcome Roser Coll, Partner at Probate in Spain by Temis & Co who will be presenting our next Certainty Expert Webinar . The webinar is aimed to provide information and practical advice about what happens when someone passes away with assets in Spain. We will address how COVID-19 has affected the execution of an inheritance in Spain and will answer general questions regarding cross-border estates between the UK and Spain. If you have a client who is about to receive an inheritance with assets in Spain whether the deceased owned property, bank accounts, stocks and shares, cars, etc this webinar shall be of interest. Do not forget how important is to deal with an English speaking Spanish solicitor when a case involving Spanish assets is addressed to you in the UK. Webinar Agenda:
Inheritance Tax and other relevant taxes
Special changes due to COVID-19
Effects of COVID-19 in the process of selling a property inherited in Spain. Reduced administrative services. Frequently Asked Questions
Join us for our next free Certainty Expert Webinar on Thursday 9th July 2020 at 12.00pm.Places on the webinar are limited so book now.

Certainty Expert Webinar presents Roser Coll

Les effectifs d’Audemars devraient bien croître à Temis
Audemars Piguet France (siège à Paris /75 – manufacture d’horlogerie – CA légal 2016 : 32 266 000€) a inauguré le 28 mai son nouveau centre européen de service après-vente, installé au sein d’un bâtiment tout neuf construit sur le pôle Temis, à Besançon /25 [cf. notre article du 6 mars 2018]. Ledit centre emploie aujourd’hui 33 personnes. Comme spécifié dans notre article précédent, des recrutements devraient avoir lieu sur place : Audemars Piguet sera en mesure d’y héberger jusqu’à 50 collaborateurs.

Les effectifs d’Audemars devraient bien croître à Temis

Le très discret SAV du prestigieux fabricant de montres AUDEMARS PIGUET / T : 03.81.41.86.60 va quitter le parc La Fayette. Mais il reste à Besançon (Doubs) et s’installera dans un bâtiment tout neuf, au sein de la technopole Temis. L’établissement bisontin emploie 25 personnes. Temis participe d’ailleurs au renouveau de l’industrie horlogère française puisque la société PHENOMEN , jusque là hébergée justement sur le parc d’activités technologiques Temis, a récemment pris son envol et occupe désormais ses propres locaux à Besançon. www.audemarspiguet.com/fr  
Information Economique Similaire

HORLOGERIE/SERVICES : Audemars Piguet s’installe sur le Parc Temis

Votre email
Spécialisé dans la conception, l’installation et la maintenance d’engins de levage, le groupe nivernais Kremer a lancé sa propre application de maintenance, Temis. Avec Temis, le groupe Kremer accélère sa mutation numérique © Kremer
A lire aussi
Implanté à Guérigny dans la Nièvre et à Dijon en Côte-d’Or, le groupe Kremer (38 salariés, 4,5 millions d’euros de chiffre d’affaires en 2017) est spécialisé dans la fabrication de matériel de levage depuis 1977. Pour simplifier et rendre encore plus fiable la maintenance des équipements qu’ils conçoivent et installent, le groupe Kremer a lancé sa propre application, Temis. "Nous sommes partis du constat que l’industrie était en train de se digitaliser", explique Laurence Lagoutte, qui gère aujourd’hui avec son frère Sébastien Kremer le groupe familial créé par leur père. Après deux ans de recherche et développement et de tests, Laurence Lagoutte et Sébastien Kremer ont décidé de créer KLS Numérique, une nouvelle société émanant du groupe Kremer, essentiellement dédiée au développement du nouvel outil numérique. Toutes les informations à portée de main
"De par notre activité initiale, nous réalisons des contrôles périodiques chez certains de nos clients. Et ces derniers nous ont souvent remonté toute la complexité à retrouver l’ensemble des éléments d’une même machine", confie Laurence Lagoutte. Equipés d’une tablette et de l’application Temis, les industriels ne seront plus confrontés à ce problème. Chaque opérateur, lors de contrôles périodiques réglementaires ou d’autres procédures internes, n’aura qu’à flasher le code de l’équipement à contrôler, ou le rentrer manuellement ou encore rechercher l’équipement dans la base de données de l’entreprise. Il aura ainsi accès à l’ensemble de la documentation de l’équipement et aux observations émises lors des précédents contrôles, grâce à un système de back office. Le tout, sans avoir recours à une connexion internet, grâce à un système de synchronisation de départ et de retour. L'outil permettra aussi une centralisation des données et une vision plus globale du parc équipementier. "Ce sont toujours les clients qui font avancer"
Si l’application Temis en est déjà à sa 26ème version, l’outil numérique développé par le groupe Kremer et aujourd’hui entre les mains de KLS Numérique est en constante évolution pour répondre au mieux aux besoins des usagers. En effet, après l’avoir testé sur leur propre parc, le groupe Kremer espère bien commercialiser ce nouvel outil sous forme d’abonnement. La tablette coûtera 1000 euros et l’abonnement variera en fonction de la taille de l’entreprise, de 1000 euros par an pour 100 équipements à près de 9000 euros pour plus de 15 000 équipements. "Parce que l’application doit servir à améliorer la maintenance des équipements d’une société, nous avons fait le choix de proposer un système d’abonnement pour pouvoir continuer à mettre à jour l’application via un cloud, explique la présidente de KLS Numérique.

Avec Temis, le groupe Kremer accélère sa mutation numérique

Ouest-France publishes a daily French newspaper. It covers sports, the economy, companies, TV programs, hobbies, and other news. It was founded in 1990 and is based in Rennes, France.

Ouest-France

Sipa Ouest-France chose TEMIS as a strategic partner to complete this project , and will integrate the latest version of its semantic content enrichment solution Luxid ® 7 , its ontology management application Luxid ® WebStudio as well as several specific annotators dedicated to media applications .

Paris, France, November 12, 2015.
Sipa-Ouest-France Group Chooses TEMIS to Enrich its Content Collection - Expert System

unicancer groups together the French comprehensive cancer centers, which are private, not-for-profit hospitals. FCCCs are dedicated to fighting cancer through a threefold mission of patient care, research, and education. They contribute to the public hospital service in accordance with statutory fees, with no additional charge.

unicancer

TEMIS , the leading provider of Semantic Content Enrichment solutions for the Enterprise , today announced that its solution Luxid has been chosen by France 's UNICANCER , the Federation of French Cancer Centers , as the semantic module for its ConSoRe project driven by SWORD Consulting and Services .

Rockville, MD, USA – March 9, 2015.
France’s UNICANCER chooses TEMIS and SWORD to Accelerate Clinical Research by Analyzing Patients’ Electronic Health Records - Expert System

Thieme Publishers

TEMIS , the leading provider of Semantic Content Enrichment solutions for the Enterprise , today announced that Thieme , the renowned German medical publisher based in Stuttgart , has chosen TEMIS 's Luxid to help its teams manage their thesauri and terminologies .

TEMIS and Thieme January 20, 2015 8:00 AM.
Thieme Chooses TEMIS's Luxid® Webstudio for Thesaurus Management - Yahoo Finance

American Society for Cell Biology (ASCB) is an inclusive, international community of scientists in cell biology and biomedical research. The company specializes in cell biology, biomedical research, genetics, neuroscience, biophysics, and more. ASCB was founded in 1960 and is based in Rockville, Maryland.

American Society for Cell Biology

CABI aims to improve people's lives by providing information to solve problems in agriculture and the environment. It is based in Wallingford, Oxfordshire.

CABI

Acquired

TEMIS, founded in 2000, has developed the flagship Luxid platform, that helps organizations extract insights from their content to manage their business more efficiently. Luxid counts many prestigious references such as Agence France Presse, BASF, Bayer Schering Pharma, Bloomberg BNA, BNP Paribas, Editions Lefebvre-Sarrut, Elsevier, EMC, Novartis, Sanofi, Thomson Reuters, The McGraw-Hill Companies, Volkswagen, as well as governmental and international organizations such as the US Department of Agriculture, the OECD, and the IMF.

Date	Round	Amount	Investors	Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.	Revenue	Sources
5/28/2015	Acquired		Expert System		0 FY undefined	1
	Other Investors		Subscribe to see more		0 FY undefined	0

Date	5/28/2015
Round	Acquired	Other Investors
Amount
Investors	Expert System	Subscribe to see more
Valuation
Revenue	0 FY undefined	0 FY undefined
Sources	1	0

First funding	Last Funding	Investor	Rounds	Board Seats	Type	Location
5/28/2015	5/28/2015	Expert System	1 Acquired		Corporation	Italy
		Omnes Capital	Subscribe to see more		Private Equity	France

First funding	5/28/2015
Last Funding	5/28/2015
Investor	Expert System	Omnes Capital
Rounds	1 Acquired	Subscribe to see more
Board Seats
Type	Corporation	Private Equity
Location	Italy	France

Date	6/27/2013
Investment Stage
Companies	i3 Analytics
Valuation	$99M
Total Funding
Note	Acquired
Sources	1

Wells Fargo Success Story

Professional Services

Platform Overview

TEMIS

Investors Count

Funding, Valuation & Revenue

This profile has not been claimed.

TEMIS Investors

TEMIS Acquisitions

1 Acquisition

Discover the right solution for your team